A trial evaluating the efficacy of cell therapy based on autologous platelet-rich plasma (PRP) for the treatment of Achilles and Patellar tendinopathies

Double-blind randomized controlled trial to evaluate the efficacy of cell therapy based on autologous platelet-rich plasma (PRP) for the treatment of Achilles and patellar tendinopathies

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN85334402

Enrollment

128

Registered

2013-11-11

Start date

2013-10-08

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Achilles tendinopathy, patellar tendinopathy Musculoskeletal Diseases Achilles tendinitis

Interventions

The subjects will be randomized to one of two groups. The first group will receive PRP and the second PPP as a therapeutic agent in a double-blinded methodology. Each subject will receive two ultrasou

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. History (> 6 weeks) of exercise-associated pain along the proximal insertion of the patellar tendon or the Achilles tendon 2. Being at least 18 and no more than 60 years old, either sex 3. Radiologic confirmation of the tendinopathy (MRI or ultrasound) 4. Patient who has signed an informed consent

Exclusion criteria

Exclusion criteria: 1. Absence of informed consent/participation in some other clinical trial 2. Presence of inflammatory?rheumatoid or systemic conditions 3. Presence or history of complications of important lower limb injuries 4. Presence of acute affections of the lower limb (i.e., infection, tendon rupture) 5. Patients requiring non-steroidal anti-inflammatory drug (NSAID) treatment for other type of affections 6. Patients undergoing medical treatment that could inhibit tendinopathies (i.e., fluoroquinolones)

Design outcomes

Primary

Measure	Time frame
1. The Victorian Institute of Sport Assessment Questionnaire (VISA-A for Achilles tendinopathy and VISA-P for patellar tendinopathy, to assess the severity of symptoms in patients with tendinopathy) 2. For the Achilles tendinopathy: Foot and Ankle Ability Measure (FAAM) (to assess the symptoms and function of the ankle and foot) 3. Visual analogue scale (VAS): The VAS-pain and will be measured with a scaled line from 0 to 10 cm. The subject will indicate on the scale the level of their pain during the last week before the scheduled visit. 4. Ultrasonographic imaging done prior to the first injection and after the treatment 5. Demographic variables (name, address, age, gender, telephone number) 6. Medical history (i.e., lower limb injuries and previous medical treatments) 7. Clinical examination of the affected region 8. Sports participation: type and level of sport and mean hours of sports participation	—

Measure

Time frame

1. The Victorian Institute of Sport Assessment Questionnaire (VISA-A for Achilles tendinopathy and VISA-P for patellar tendinopathy, to assess the severity of symptoms in patients with tendinopathy) 2. For the Achilles tendinopathy: Foot and Ankle Ability Measure (FAAM) (to assess the symptoms and function of the ankle and foot) 3. Visual analogue scale (VAS): The VAS-pain and will be measured with a scaled line from 0 to 10 cm. The subject will indicate on the scale the level of their pain during the last week before the scheduled visit. 4. Ultrasonographic imaging done prior to the first injection and after the treatment 5. Demographic variables (name, address, age, gender, telephone number) 6. Medical history (i.e., lower limb injuries and previous medical treatments) 7. Clinical examination of the affected region 8. Sports participation: type and level of sport and mean hours of sports participation

—

Secondary

Measure	Time frame
Rapport of the overall satisfaction of the procedure as well as the impression of the response to the treatment. These parameters will be measured with a scaled line from 0 to 10 cm. These outcomes will be measured at baseline, 4 weeks, 2 months, 4 months and 12 months.	—

Countries

Switzerland

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026